Identification of a potential inhibitor for New Delhi metallo-β-lactamase 1 (NDM-1) from FDA approved chemical library- a drug repurposing approach to combat carbapenem resistance.

Autor: S S; Department of Biological Sciences, School of Basic & Applied Sciences, Dayananda Sagar University, Bangalore, Karnataka, India., N H; Department of Biological Sciences, School of Basic & Applied Sciences, Dayananda Sagar University, Bangalore, Karnataka, India., Fasim A; Department of Biological Sciences, School of Basic & Applied Sciences, Dayananda Sagar University, Bangalore, Karnataka, India., More SS; Department of Biological Sciences, School of Basic & Applied Sciences, Dayananda Sagar University, Bangalore, Karnataka, India., Das Mitra S; Department of Biological Sciences, School of Basic & Applied Sciences, Dayananda Sagar University, Bangalore, Karnataka, India.
Jazyk: angličtina
Zdroj: Journal of biomolecular structure & dynamics [J Biomol Struct Dyn] 2023 Sep-Oct; Vol. 41 (16), pp. 7700-7711. Date of Electronic Publication: 2022 Sep 27.
DOI: 10.1080/07391102.2022.2123402
Abstrakt: Superbugs producing New Delhi metallo-β-lactamase 1 (NDM-1) enzyme is a growing crisis, that is adversely affecting the global health care system. NDM-1 empowers the bacteria to inactivate entire arsenal of β-lactam antibiotics including carbapenem (the last resort antibiotic) and remains ineffective to all the available β lactamase inhibitors used in the clinics. Limited therapeutic option available for rapidly disseminating NDM-1 producing bacteria makes it imperative to identify a potential inhibitor for NDM-1 enzyme. With drug repurposing approach, in this study, we used virtual screening of available Food and Drug Administration (FDA) approved chemical library (ZINC 12 database) and captured 'adapalene' (FDA drug) as a potent inhibitor candidate for NDM-1 enzyme. Active site docking with NDM-1, showed adapalene with binding energy -9.21 kcal/mol and interacting with key amino acid residues (Asp124, His122, His189, His250, Cys208) in the active site of NDM-1. Further, molecular dynamic simulation of NDM-1 docked with the adapalene at 100 ns displayed a stable conformation dynamic, with relative RMSD and RMSF in the acceptable range. Subsequently, in vitro enzyme assays using recombinant NDM-1 protein demonstrated inhibition of NDM-1 by adapalene. Further, the combination of adapalene plus meropenem (carbapenem antibiotic) showed synergistic effect against the NDM-1 producing carbapenem (meropenem) resistant clinical isolates ( Escherichia coli and Klebsiella pneumoniae ). Overall, our data indicated that adapalene can be a potential inhibitor candidate for NDM-1 enzyme that can contribute to the development of a suitable adjuvant to save the activity of carbapenem antibiotic against infections caused by NDM-1 positive gram-negative bacteria. Communicated by Ramaswamy H. Sarma.
Databáze: MEDLINE